medigraphic.com
ISSN 1561-2945 (Print)

2011, Number 3

<< Back Next >>

Revista Cubana de Cirugía 2011; 50 (3)

Prognostic value of basal lipid fractions in patients operated on of myocardial revascularization with extracorporeal circulation

Llanes EJR, Ortega TY, Rodríguez NL, Paredes CA, Mojena MG, Ramírez LM, Pérez LH, Solís CM, Bacallao SJF

Language: Spanish
References: 21
Page: 324-332
PDF size: 120.54 Kb.


ABSTRACT

A prospective, longitudinal and observational study was conducted in 60 patients from January 2000-2009 to determine the prognostic value of these basal lipid fractions and its relation to occurrence of adverse clinical events in postoperative period of patients with an extracorporeal circulation myocardial revascularization indication. As result, the basal concentrations of total cholesterol, triglycerides and the cholesterol associated with high density lipoproteins (HDL) were modified during the surgical procedure and in the recovery unit. Also, it was shown a significant decrease of HDL and a trend to increase the cholesterol level as well as a close association among these events and these lipid variables (p< 0.05). We conclude that patients with an altered lipid profile basis are more liable to develop adverse clinical events in the immediate postoperative period of coronary surgery with extracorporeal circulation.


REFERENCES

  1. Rannel WB, Castelli WP, Gordon T, Mc Namara PM. Serum cholesterol, lipoproteins and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971;741-12.

  2. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature dealth from coronary heart disease continous and graded? Finding in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2833-8.

  3. Wong N, Wilson PW, Kannel WB. Serum Cholesterol as a Prognostic Factor after Myocardial Infarction. The Framingham Study. Ann Intern Medicine. 1991;115:687-93.

  4. Gordon T, Castelli WR, Hijortland MC, Kannel BW, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Heart Study. Am J Med. 1977;62:707-14.

  5. Badimón JJ, Ibáñez B. Incremento de HDL como arma terapéutica en la aterotrombosis. Rev Esp Cardiol. 2010;63(3):323-33.

  6. Sharret AR, Ballantyne CM, Coady SA, Heiss G, Sortie PD, Atelier et al. Coronary heart disease predictor from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoprotein A-I and B, and HDL density subfraction. Atherosclerosis Risk in Communites (ARIC) Study. Circulation. 2001;104:1108.

  7. Assman G, Schulte H. The importance of tryglicerides results from the Prospective Cardiovascular Munster. (PROCAM) Study. Eur J Epidemiol. 1992;8:99-103.

  8. Expert Panel on Detection. Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatmen Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA. 2001;285:2486-97.

  9. Bouziotas C, Koutedalis Y, Nevil A, Ageli E, Tsigilis N, Nikdau A. Greek adolescents fitnees, fatness, fat intakes, activity and coronary Heart disease risk. Arch Dis Child. 2004;89:41-4.

  10. Pérez PA. Ejercicio, piedra angular de la prevención cardiovascular. Rev Esp Cardiol. 2008;61:514-28.

  11. Sánchez-Benito B, Sánchez-Soriano E, Ginart-Suárez J. Evaluación de la ingesta de grasas y minerales, en un grupo de ciclistas de equipos juvenil y sub 23. Clin Invest Arterioscl. 2007;19(6):269-77.

  12. Plaza PG, Vidor AF, Mata JP, Pérez JF, Marquez GA, Casanova LJA. Control de la colesterolemia en España 2000. Un instrumento para la prevención cardiovascular. Rev Esp Cardiol. 2000;53:815-37.

  13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.

  14. Llanes Echevarría JR, Nafeh M, Ramirez LM, Milán R, Rivas W, Rodríguez RK, et al. Estudio evolutivo de un grupo de pacientes, sometidos a un método de Minicardioplejia Sanguínea Normotérmica Continua con modificaciones, durante la circulación extracorpórea. Rev Latinoamer Tecnol Extracorp. 2003;10:1.

  15. Morlans K, Sainz H, Gónzalez-Prendes CM, Morlans J. Infarto agudo de miocardio en la revascularización miocárdica. Rev Cubana Cardiol Cir Cardiovasc. 1997;11(1):5-11.

  16. Careaga G, Aguirre GG, Medina LE, Borrayo G, Prado G, Argüero R. Factores de riesgo para mediastinitis y deshicencia de esternal, después de la cirugía cardíaca. Rev Esp Cardiol. 2006;59(2):130-5.

  17. Jeppesen J, Ole Hein H, Suadicani P, Gyntelberg F. High triglycerides/low highdensity lipoprotein cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease. American Heart Journal. 2003;145(1):103-8.

  18. Hamsten A, de Faire U, Walldius G. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;4:3-9.

  19. Steinberg D, Lewis A. Conner memorial lecture, oxidative modification of LDL and atherogenesis. Circulation. 1997;95:1062-71.

  20. Gómez C. Alteraciones metabólicas y enfermedad cardiovascular. Hipertensión. 2004;21(7):331-3.

  21. Pérez-Méndez O. Lipoproteínas de alta densidad (HDL) ¿Un objetivo terapéutico en la prevención de la aterosclerosis? Rev Arch Cardiol Mex. 2004;74(1):53-67.




2020     |     www.medigraphic.com